CVR Medical Logo
CA1266321084
A2ASKP
CRRVF

CVR Medical

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • CVR Energy misses Q1 2026 forecasts significantly and reports large net loss

    CVR Energy reported Q1 2026 EPS of -1.24 USD, well below the expected -0.38 USD, while revenue of 1.98 billion USD exceeded estimates. The company recorded a consolidated net loss of 160 million USD and adjusted EBITDA of 37 million USD. Results were hurt by unrealized losses on derivative transactions and high RIN prices; the stock fell 1.58% in premarket trading. For Q2 2026 CVR expects throughput of 200,000–215,000 bpd and direct operating costs of 110–120 million USD; strategic adjustments to the crude slate are intended to improve margins. » Más en de.investing.com


  • CVR Energy hits 52-week high and offers high dividend yield

    CVR Energy’s stock rose to $33.25, marking a 52-week high and bringing market capitalization to about $3.33 billion. The yield is 11.49% and the company has paid dividends for 12 consecutive years. Despite a strong price gain of 39.4% over the past year (58.45% in six months), CVR reported an adjusted loss per share of $0.23 in Q2/2025 (expectation: -$0.06), but beat revenue expectations with $1.76 billion. Analyst notes indicate the stock may be trading above its fair value; gross profit margin remained weak at 1.63%. » Más en de.investing.com


  • CVR Energy reaches 52-week high at 32.67 USD

    CVR Energy’s stock rose to a 52-week high of 32.67 USD and has gained 70.7% over the past six months; year-to-date the increase is 49.4%. InvestingPro cites a dividend yield of 11.35% and notes 12 consecutive years of dividend payments, but considers the stock to be above its fair value. For Q2 2025 the company reported an adjusted loss per share of 0.23 USD (expectation: -0.06 USD) on revenue of 1.76 billion USD (expectation: 1.68 billion USD), after which the stock fell sharply in after-hours trading. » Más en de.investing.com


  • CVRx increases revenue but misses earnings forecast in second quarter 2025

    CVRx grew its revenue by 15% to $13.6 million in the second quarter of 2025, surpassing expectations, but reported a higher net loss of $0.57 per share compared to the forecast of $0.52. The stock saw a slight decline as profitability remains a challenge. The company is maintaining its full-year revenue guidance and is focusing on expanding in the US market and strengthening its sales team. » Más en de.investing.com


  • CVRx receives continued Medicare reimbursement for Barostim but lowers revenue forecast

    The Centers for Medicare and Medicaid Services propose to continue reimbursing CVRx's Barostim implantation procedure at around $45,000. Despite this positive regulatory development, CVRx missed revenue expectations in the first quarter and lowered its annual forecast, citing sales challenges. Analysts downgraded the stock due to ongoing uncertainties and volatile revenues. » Más en de.investing.com

Datos financieros de la empresa

En el último año, CVR Medical tuvo unos ingresos de 0 € y un beneficio neto de -1,58 M €
(EUR) 2021
YoY
Ingresos 0 -
Beneficio bruto -215,45 7,54 %
Beneficio neto -1,58 M 1012,76 %
EBITDA -602,63 mil 1587,74 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
976,31 €
Número de acciones
107,2 M
Máximo/mínimo de 52 semanas
0,0000091 € - 0,0000009 €
Dividendos No
Beta
1,82
Ratio P/E
0,00
Ratio PEG
0,00
Ratio P/B
0,00
Ratio P/S
0,00

Perfil de la empresa

CVR Medical Corp., una empresa del sector sanitario, se dedica a la investigación y el desarrollo de tecnología de análisis de ondas sonoras subsónicas, infrasónicas y de baja frecuencia para el sector sanitario. La compañía ofrece el dispositivo de escaneo de estenosis carotídea, una herramienta de diagnóstico para detectar y medir la estenosis arterial carotídea. Sus productos están destinados a pacientes, pagadores y proveedores de atención sanitaria. CVR Medical Corp. se constituyó en 1980 y tiene su sede en North Vancouver, Canadá.

Nombre
CVR Medical
CEO
Darren Day
Sede North Vancouver, bc
Canadá
Sitio web
Salida a bolsa
02/11/2016
Empleados 3

Símbolos bursátiles

Bolsa Símbolo
Pnk
CRRVF
London
0UMW.L
München
B3BN.MU
🍪

Parqet  usa cookies. Más información